Risk assessment for bleeding during warfarin therapy

December 2010
Internal Medicine Alert;12/15/2010, Vol. 32 Issue 23, p183
The article reports on the use of a stratification tool to assess the risk of bleeding in patients with atrial fibrillation while on warfarin therapy in the U.S.


Related Articles

  • Dabigatran etexilate.  // Reactions Weekly;9/21/2013, Issue 1470, p18 

    An abstract of the article "Traumatic intracranial hemorrhage in patients taking dabigatran: Report of 3 cases and review of the literature," by S. N. Wassef and colleagues is presented.

  • Dabigatran reduces heart attack, GI bleeding in real world.  // Reactions Weekly;8/10/2013, Issue 1465, p4 

    The article offers the author's insight on the role of the anticoagulants dabigatran and warfarin in heart attack and gastrointestinal (GI) bleeding. The author states that based from a study on anticoagulant-naive patients with atrial fibrillation medicated by the two agents indicate that...

  • National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Brieger, David; Amerena, John; Attia, John R.; Bajorek, Beata; Chan, Kim H.; Connell, Cia; Freedman, Ben; Ferguson, Caleb; Hall, Tanya; Haqqani, Haris M.; Hendriks, Jeroen; Hespe, Charlotte M.; Hung, Joseph; Kalman, Jonathan M.; Sanders, Prashanthan; Worthington, John; Yan, Tristan; Zwar, Nicholas A. // Medical Journal of Australia;10/15/2018, Vol. 209 Issue 8, p356 

    Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are continually evolving and care for patients requires confidence in integrating these new...

  • Flecainide.  // Reactions Weekly;12/2/2016, Vol. 1630 Issue 1, p110 

    An abstract of the article "Use of anti arrhythmic drugs (AAD) in management of patients with atrial fibrillation (AF), single center experience" by M.A. Ahmed and others is presented.

  • Fatigue in a Patient with Atrial Fibrillation. Germano, Joseph J.; Steingart, Richard M. // Cortlandt Forum;8/25/2002, Vol. 15 Issue 8, p68 

    Describes a case of fatigue in a patient with atrial fibrillation. Reason for administration of amiodarone; Multiorgan side effects of amiodarone; Characteristics and physiologic effects of amiodarone.

  • The P450 system and CV outcomes with clopidogrel. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the impact of the P450 system and clopidogrel on the reduction of cardio-vascular events (CV) among people with atrial fibrillation.

  • Risk assessment for bleeding during warfarin therapy. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the role of the HAS-BLED stratification tool in evaluating one-year risk of bleeding in patients with atrial fibrillation (AF) who were undergoing warfarin therapy.

  • Rivaroxaban Tablets (Xarelto®). Elliott, William T.; Chan, James // Internal Medicine Alert;12/15/2011, Vol. 33 Issue 23, p181 

    The article reports that an oral factor xa inhibitor named Rivaroxaban has been approved for minimizing the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).

  • European AF patients at risk due to missed opportunities.  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p6 

    The article discusses a report which revealed that poor diagnosis, failure to follow treatment guidelines, and lack of quality patient information result to unnecessary costs and risks to patients with atrial fibrillation (AF) in Europe.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics